August 29, 2019
Ono Pharmaceutical said on August 28 that it has submitted a regulatory application for its BTK inhibitor tirabrutinib (ONO-4059) in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL). Since the drug is granted orphan...read more